VectivBio Holding, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, has announced the pricing of a USD 125 m underwritten offering of ordinary shares. The underwritten offering consists of 16,700,000 ordinary shares at an offering price of USD 7.50 per share. Investors include Cowen Healthcare Investments, Driehaus Capital Management, Eventide Asset Management, Forbion’s Growth Opportunities Fund, Frazier Life Sciences, Marshall Wace, OrbiMed, Surveyor Capital (a Citadel company), TCG X, Venrock Healthcare Capital Partners and Vivo Capital, among other specialist biotech investors. Before deducting the underwriting discounts and commissions and offering expenses, VectivBio expects to receive total gross proceeds of approximately $125 million.
The Basel based company has also announced the release of its interim data from the first five of nine patients in its ongoing Phase 2 STARS Nutrition clinical trial, and an amendment to its financing agreement with the UK Kreos Capital VI, including the right to receive additional warrants under certain conditions.
The Homburger team includes partner Andreas Müller (pictured), associates Margrit Marti and Oliver Kneubühl, and junior associate Julien Di Sabato (all capital markets, corporate/m&a), partner Jürg Frick, associates Simone Gloor and Stefan Bindschedler, and junior associate Thibault Sieber (all financing and investment products), partner Stefan Oesterhelt and associate Kevin Müller (both tax), and partner Luca Dal Molin (IP / IT).